CBP-501 is under clinical development by CanBas and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBP-501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBP-501 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), mesothelioma, head & neck cancer, ovarian cancer, endometrial cancer, breast cancer, bladder cancer, kidney cancer, esophageal cancer, gastric cancer, colon cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, soft tissue sarcoma, and osteosarcoma. The drug candidate is administered through intravenous route as a form of infusion. CBP-501 is a G2 checkpoint inhibitor. It is a peptide with G2 checkpoint-abrogating activity. CBP-501 targets multiple serine/threonine kinases, including MAPKAP-K2, C-Tak1, and CHK1 and CHK2. The drug candidate was also under development for refractory ovarian cancer.G M T
CanBas, operates as a clinical stage biopharmaceutical company. It develops therapeutics for cancer. The company discovers and develops novel therapeutics in the field of oncology targeting the cell cycle. It provides two clinical oncology programs, CBP501 and CBS9106 with mutually unique MoAs. CanBas product carries out development in CBP501; a modified synthetic peptide enhances the efficacy of cisplatin without adding toxicity. CanBas’ CBP501 is in US Phase II development for first-line treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer. The company’s other drug candidates, CBS9106, an orally-active synthetic small molecule of molecular mass 420, is in the preclinical stage. It also develops techniques to determine the drug-specific sensitivity of individual cancer from a patient. CanBas is headquartered in Numazu, Japan.
For a complete picture of CBP-501’s drug-specific PTSR and LoA scores, buy the report here.